TS03 Inc Trust Units TSTIF

RE:RE:RE:RE:$$$$

[binjo222]

echo2, thank you for your explanation of critical & semi-critical.  Your expertise is appreciated.

June has brought us a new perspective on TSO3's value.  On June 9th the FDA launched a surprise requiring sterilization for new flexible scopes or upgrades to current scopes.  They didn't say how this is supposed to happen, but TSO3 is the clear leader in this area.  Then five days later RR announced there will be a submission on the Olympus and Pentax duodenscopes.  This should clear any lingering doubt about TSO3 as the front runner in this area.

That of course is the future.  The Olympus & Pentax clearances should also have a near term effect.  As has been discussed on this board, some hospitals will likely go with the VP4 to cover liability issues if they continue to only disinfect.  Obviously good for TSO3, but I think the FDA will look very favorably on this too.  They know they have a serious problem with contamination, but they can't order all flexible scopes to be sterilized.  There just aren't enough VP4s or the ability to produce them.  The FDA can't order something that is impossible in a practical sense.  But if hospitals adopt VP4 sterilization on their own, the problem begins to be addressed.  After the Pentax and Olympus clearances are granted, I would expect RR to put in for another scope or two or three.  And when those clearances come through, more hospitals should move to the VP4.  It's possible that sterilization of flexible scopes could become the defacto industry standard before it is mandated by the FDA.

I just hope the Olympus and Pentax clearances wake the market up to TSO3's real value.  And of course none of this is happening in a vaccmue.  I expect a take over attempt by one (hopefully more) of the big players.  I just hope our board fights for the company's real value.